Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) just unveiled an update.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This announcement outlines the leadership structure, which includes both executive and independent non-executive directors, and details the membership of four key board committees. This update is significant for stakeholders as it provides clarity on the governance and strategic oversight within the company, potentially impacting its decision-making and operational focus.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, focusing on the development and production of pharmaceutical products. The company is involved in the healthcare industry, providing various pharmaceutical solutions to the market.
Average Trading Volume: 1,034,778
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.14B
Find detailed analytics on 9989 stock on TipRanks’ Stock Analysis page.